Lloyd Haskell

4.3k total citations · 2 hit papers
69 papers, 2.1k citations indexed

About

Lloyd Haskell is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Lloyd Haskell has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Cardiology and Cardiovascular Medicine, 28 papers in Surgery and 26 papers in Internal Medicine. Recurrent topics in Lloyd Haskell's work include Venous Thromboembolism Diagnosis and Management (26 papers), Peripheral Artery Disease Management (24 papers) and Atrial Fibrillation Management and Outcomes (19 papers). Lloyd Haskell is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (26 papers), Peripheral Artery Disease Management (24 papers) and Atrial Fibrillation Management and Outcomes (19 papers). Lloyd Haskell collaborates with scholars based in United States, Germany and Canada. Lloyd Haskell's co-authors include Theodore E. Spiro, Alex C. Spyropoulos, Alexandre Mebazaa, Dayi Hu, Harry R. Büller, Geno J. Merli, Victor F. Tapson, Sebastian Schellong, Russell D. Hull and Rupert Bauersachs and has published in prestigious journals such as New England Journal of Medicine, Circulation and Blood.

In The Last Decade

Lloyd Haskell

60 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

2017 492 citations Rupert Bauersachs, Lloyd Haskell et al. New England Journal of Medicine profile →
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

2013 436 citations Alexander T Cohen, Theodore E. Spiro et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lloyd Haskell United States	22	1.3k	1.3k	563	247	247	69	2.1k
Alex Gold United States	20	945 0.7×	1.1k 0.9×	487 0.9×	184 0.7×	100 0.4×	42	2.0k
J Weitz Canada	14	1.5k 1.1×	845 0.7×	401 0.7×	456 1.8×	206 0.8×	22	2.1k
Majed A. Refaai United States	27	831 0.6×	985 0.8×	512 0.9×	762 3.1×	174 0.7×	108	3.0k
Melissa Forgie Canada	11	1.9k 1.4×	939 0.7×	752 1.3×	605 2.4×	199 0.8×	16	2.8k
B. J. Hunt United Kingdom	11	856 0.6×	549 0.4×	532 0.9×	377 1.5×	172 0.7×	19	2.2k
Alfonso Tafur United States	29	1.7k 1.3×	1.4k 1.1×	558 1.0×	219 0.9×	223 0.9×	135	2.5k
Huyen Tran Australia	23	742 0.6×	735 0.6×	453 0.8×	813 3.3×	150 0.6×	128	2.0k
Theodore E. Spiro United States	29	2.5k 1.9×	2.3k 1.8×	879 1.6×	319 1.3×	250 1.0×	66	3.4k
Rachel Rosovsky United States	25	1.7k 1.3×	885 0.7×	446 0.8×	324 1.3×	309 1.3×	143	3.0k
Dorothy Adcock United States	28	1.1k 0.8×	1.1k 0.8×	436 0.8×	807 3.3×	252 1.0×	78	2.8k

Countries citing papers authored by Lloyd Haskell

Since Specialization

Citations

This map shows the geographic impact of Lloyd Haskell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd Haskell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd Haskell more than expected).

Fields of papers citing papers by Lloyd Haskell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd Haskell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd Haskell. The network helps show where Lloyd Haskell may publish in the future.

Co-authorship network of co-authors of Lloyd Haskell

This figure shows the co-authorship network connecting the top 25 collaborators of Lloyd Haskell. A scholar is included among the top collaborators of Lloyd Haskell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lloyd Haskell. Lloyd Haskell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Szarek, Michael, E. Sebastian Debus, Mark R. Nehler, et al.. (2025). Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. Journal of the American Heart Association. 14(21). e039752–e039752.

Bakris, George L., et al.. (2024). Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. American Journal of Hypertension. 37(6). 438–446.

Yuan, Žhong, Bennett Levitan, Hsiaowei Deng, et al.. (2024). Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association. 13(8). e032782–e032782. 3 indexed citations

Canonico, Mario Enrico, Cecilia C. Low Wang, Judith Hsia, et al.. (2024). Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. Journal of the American College of Cardiology. 84(9). 801–811. 2 indexed citations

Debus, E. Sebastian, Mark R. Nehler, Manesh R. Patel, et al.. (2024). Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation. 149(8). 635–637. 2 indexed citations

Rymer, Jennifer A., Sonia S. Anand, E. Sebastian Debus, et al.. (2023). Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 148(24). 1919–1928. 5 indexed citations

Ammann, Eric M., Dejan Milentijevic, Darren A. Talbot, et al.. (2023). Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US. Heliyon. 9(2). e13258–e13258. 2 indexed citations

Bakris, George L., John M. Flack, Krzysztof Narkiewicz, et al.. (2023). Effects of Aprocitentan for Blood Pressure Lowering and Proteinuria in Patients with CKD and Resistant Hypertension. Journal of the American Society of Nephrology. 34(11S). 56–56. 2 indexed citations

Bakris, George L., et al.. (2023). Association of uncontrolled blood pressure in apparent treatment‐resistant hypertension with increased risk of major adverse cardiovascular events plus. Journal of Clinical Hypertension. 25(8). 737–747. 6 indexed citations

10.

Berkowitz, Scott D., Rupert Bauersachs, Michael Szarek, et al.. (2022). Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of Thrombosis and Haemostasis. 20(5). 1193–1205. 7 indexed citations

11.

Hess, Connie N., Iris Baumgärtner, Sonia S. Anand, et al.. (2022). Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association. 11(12). e024655–e024655. 7 indexed citations

12.

Lipardi, Concetta, C. Gregory Elliott, Lloyd Haskell, et al.. (2021). Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clinical and Applied Thrombosis/Hemostasis. 27. 2975234820–2975234820. 1 indexed citations

13.

Hiatt, William R., Manesh R. Patel, Sonia S. Anand, et al.. (2021). EFFICACY AND SAFETY OF LOW-DOSE RIVAROXABAN IN SYMPTOMATIC PAD PATIENTS UNDERGOING REVASCULARIZATION CURRENTLY SMOKING: INSIGHTS FROM VOYAGER PAD. Journal of the American College of Cardiology. 77(18). 1808–1808.

14.

Cohen, Alexander T., Theodore E. Spiro, Alex C. Spyropoulos, et al.. (2014). D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. Journal of Thrombosis and Haemostasis. 12(4). 479–487. 90 indexed citations

15.

Bookhart, Brahim, Lloyd Haskell, Luke Bamber, et al.. (2014). Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. Journal of Medical Economics. 17(10). 691–695. 37 indexed citations

16.

Cohen, Alexander T, Theodore E. Spiro, Harry R. Büller, et al.. (2013). Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine. 368(6). 513–523. 436 indexed citations breakdown →

17.

Spiro, Theodore E., Harry R. Büller, Lloyd Haskell, et al.. (2011). Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. Journal of Thrombosis and Thrombolysis. 31(4). 407–416. 91 indexed citations

18.

Bucher, Michael, N. R. Bohidar, Lloyd Haskell, et al.. (2008). Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist. Clinical Pharmacology & Therapeutics. 85(2). 145–148. 1 indexed citations

19.

Pfister, Marc, Nancy Martin, Lloyd Haskell, & Jeffrey S. Barrett. (2004). Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240. The Journal of Clinical Pharmacology. 44(6). 621–631. 11 indexed citations

20.

Haskell, Lloyd, Daniel Glicklich, & David Senitzer. (1988). HLA Associations in Heroin-Associated Nephropathy. American Journal of Kidney Diseases. 12(1). 45–50. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact